Ncardia, a Gosselies, Belgium-based drug discovery and development stem cell technology company, completed a €10.5m series B financing round.
The round was led by Épimède, with participation from InnovationQuarter, SRIW, SambrInvest, Vesalius Biocapital and SFPI-FPIM.
The company intends to use the funds to accelerate its international growth, to develop safety assays and to expand capabilities in the cardiovascular drug discovery and high throughput screening domain.
Led by Stefan Braam, CEO, Ncardia produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, the company develops and commercializes assay services for drug safety and efficacy testing.
Additionally the company has built up a portfolio of patents covering the use of stem cell models for these applications.
Ncardia – established following the merger of Pluriomics and Axiogenesis – is also based in the Netherlands, Germany and the USA.